Finn
GMAB Biotechnology · Cancer drugs · Late-stage pipeline · Thesis updated November 8, 2026

Stunning trial data accelerates the Genmab biotech pivot

01 Running thesis

A cash-rich pivot with massive clinical wins

Genmab is changing its story. For years, much of the money came from royalties on partner sales of drugs like DARZALEX. Now the company wants to become a full biotech, meaning it develops drugs, runs trials, and sells more products itself.

The bull case is that the old royalty stream gives Genmab time and cash to build the new model, and that model is succeeding. Commercial execution is strong. EPKINLY reached $491 million in sales in the first nine months of 2026, up 47 percent from a year earlier.

October 2026 removed massive clinical risk. Genmab delivered highly successful late-stage trial results across three key assets. EPKINLY cut the risk of disease progression or death by 51 percent in frontline lymphoma. Rina-S showed a 71 percent reduction in progression risk for ovarian cancer. Petosemtamab cut the risk of death by half in head and neck cancer.

The bear case is concentration and timing. DARZALEX royalties are still the main profit base, and Genmab says U.S. daratumumab patents expire in 2029, when royalties should begin to fall materially. The stock needs the new late-stage data to turn into rapid approvals and sales before that royalty cliff matters.

Nov 2026▲Management highlighted three unprecedentedly positive Phase III readouts in October 2026 for EPKINLY, Rina-S, and petosemtamab. EPKINLY sales also hit $491 million in the first nine months, up 47 percent year over year.
Aug 2026▲Management set Q4 2026 as a major catalyst window with data expected for EPKINLY, Rina-S, and petosemtamab. EPKINLY sales also reached $312 million in the first half of the year, up 48 percent.
May 2026▲Q1 2026 showed strong EPKINLY execution, with global sales reaching $137 million and growing 52 percent year over year. Rina-S timing also improved because the Phase III RAINFOL-02 trial finished enrollment early.
May 2026▼The frontline petosemtamab head and neck cancer trial was increased from 500 to 700 patients. Management called it a probability of success step, but the exact reason remains an open question.
Feb 2026→The 2025 annual filing confirmed that Merus had closed, adding petosemtamab, BIZENGRI, and new antibody platforms. It also confirmed $5.5 billion of acquisition debt, adding balance sheet risk to the growth story.
Feb 2026▼EPCORE DLBCL-1 missed its overall survival endpoint in monotherapy. Management cited COVID-19 and more available bispecific drugs, but the miss adds regulatory and perception risk for EPKINLY.
Nov 2025▲Genmab's planned Merus acquisition strengthened the owned asset strategy by adding petosemtamab. The same update showed portfolio discipline, with GEN1042 stopped in frontline head and neck cancer.
Aug 2025▲EPKINLY delivered positive Phase III follicular lymphoma results, meeting both progression-free survival and response endpoints. Genmab also added a Rina-S plan in non-small cell lung cancer.
02 Business model

Royalties pay for owned launches

Genmab makes money in several ways. The biggest is royalties, which are payments based on sales of drugs that partners sell. In 2025, royalties were $3.102 billion out of $3.720 billion of total revenue, or about 83 percent of revenue.

The faster-growing part is direct and partnered product sales. Genmab records EPKINLY net product sales in the U.S. and Japan under its AbbVie partnership. It also records or shares economics from Tivdak, depending on the country. In the first nine months of 2026, EPKINLY reached $491 million in sales, while Tivdak reached $131 million.

The Merus acquisition pushes Genmab further toward owning more of its future. It added petosemtamab, BIZENGRI royalties, and antibody technology platforms. The tradeoff is financial. Genmab took on heavy debt for the deal, with $4.1 billion effectively fixed at about a 6.6 percent interest rate, and management wants gross leverage below 3x by the end of 2027.

03 Product portfolio

The drugs that matter

Cash cow

DARZALEX royalties

DARZALEX is sold by J&J, while Genmab receives royalties. It is the main cash source today, but U.S. patent rights on daratumumab expire in 2029.

Growth engine

EPKINLY

EPKINLY is a bispecific antibody. Sales reached $491 million in the first nine months of 2026, and spectacular frontline lymphoma trial data expands its future market.

Steady

Tivdak

Tivdak is an antibody drug conjugate. First nine months of 2026 sales reached $131 million, and Genmab is taking more responsibility outside the U.S. and China.

Growth engine

Rina-S

Rina-S is a late-stage antibody drug conjugate aimed at ovarian and endometrial cancers. It delivered highly compelling progression-free survival data in October 2026.

Growth engine

Petosemtamab

Petosemtamab came with the Merus deal. It showed a major overall survival benefit in frontline head and neck cancer and is expanding into colorectal cancer trials.

Steady

BIZENGRI

BIZENGRI was added through Merus and gives Genmab another royalty medicine, though management does not expect the revenue to be material.

04 Business segments

Revenue still starts with royalties

Royalties83%modest
Net product sales10%growing fast
Milestone revenue3%flat
Collaboration revenue2%modest
Reimbursement revenue1%declining
License fees0%flat

The mix uses 2025 revenue by type from Genmab's Annual Report Note 2.1. Royalties are the clear majority, so the company is still exposed to partner sales and patent timing even as owned product sales grow.

05 Risk factors

What could break the thesis

DARZALEX royalty cliff

High impact · High odds

DARZALEX royalties are the main profit base. Genmab says U.S. daratumumab patent rights expire in 2029 and royalties should begin to decline materially after that. If the new pipeline drugs do not scale fast enough, earnings power could fall.

We watchTrack DARZALEX royalty revenue, partner DARZALEX sales, and Genmab's 2029 royalty commentary.

Regulatory delays for new data

High impact · Medium odds

Genmab generated fantastic trial data in late 2026 for EPKINLY, Rina-S, and petosemtamab. The risk now shifts to regulatory execution. Any delay from the FDA or limited label wording would slow the commercial launch for these major growth drivers.

We watchWatch for FDA acceptance of filings and subsequent label approvals in 2027.

Petosemtamab competitive pressure

Medium impact · Medium odds

In head and neck cancer, petosemtamab faces intense competitive pressure from Johnson and Johnson's amivantamab. Genmab claims a massive safety advantage, but if doctors do not see the differentiation, the drug could lose market share.

We watchWatch commercial adoption of amivantamab and the next head and neck cancer readouts in 2027.

Debt and integration load

Medium impact · Medium odds

The Merus deal added $5.5 billion of debt and integration work. Genmab says $4.1 billion is effectively fixed at about a 6.6 percent interest rate and targets gross leverage below 3x by the end of 2027. If trial costs rise, that deleveraging plan becomes harder.

We watchTrack gross leverage, interest expense, operating cash flow, and Merus integration costs through 2027.
06 Quick answers

In one breath

What does Genmab actually do?

Genmab develops antibody drugs, mostly for cancer. It also earns royalties when partners sell medicines that use Genmab science, with DARZALEX being the biggest example.

Why is DARZALEX so important to Genmab?

DARZALEX royalties are the largest part of revenue and help fund Genmab's pipeline. The risk is that U.S. patent rights on daratumumab expire in 2029, when those royalties are expected to decline materially.

What is the main bull case for GMAB stock?

The bull case is that Genmab is successfully using royalty cash to build a stronger owned drug business. Late 2026 data for EPKINLY, Rina-S, and petosemtamab was highly positive, which could widen the future revenue base.

What should investors watch in 2027?

The biggest items are FDA approvals for Rina-S, petosemtamab, and EPKINLY based on their recent clinical trial wins. Investors should also watch whether Genmab keeps lowering its debt leverage after the Merus acquisition.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Genmab Q3 2026 Earnings Call Transcript
  2. Genmab 2025 Form 20-F
08 Explore the industry

Comparable Biotechnology companies

Companies near Genmab A/S in Finn's Biotechnology industry ranking.

Get started with Finn today